Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527475 · ClinicalTrials.gov registry record · Phase 2
Ranibizumab and Reduced Fluence PDT for AMD
A Phase 2 study, sponsored by Texas Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00527475: Completed Phase 2 study, sponsored by Texas Retina Associates.
NCT00527475 is a Phase 2 study that has completed, run by Texas Retina Associates. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00527475, a Phase 2 study, has completed, sponsored by Texas Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.
Interventions
- DRUG ranibizumab
- DRUG verteporfin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
What the finished NCT00527475 record still lists
NCT00527475 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 2 interventions - of which ranibizumab is the first listed.
NCT00527475 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00527475 about?
NCT00527475 is a clinical study titled "Ranibizumab and Reduced Fluence PDT for AMD". Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retina...
What is the current status of trial NCT00527475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00527475?
The interventions under investigation include: ranibizumab (DRUG), verteporfin (DRUG).
Who is sponsoring clinical trial NCT00527475?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00527475's enrollment target sits among peer trials
60 1027th of 2000 higher than 868 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia